Kidney Research and Clinical Practice

Search

Page Path

HOME
Search

Review Articles

Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?: Yu-Hsiang Chou, Szu-Yu Pan, Shuei-Liong Lin; Kidney Res Clin Pract. 2023;42(1):27-38. Published online November 21, 2022; DOI: https://doi.org/10.23876/j.krcp.22.118
Cited By 4; Full text PubReader ePub PDF

Original Articles

Effects of the route of erythropoietin administration on hemoglobin variability and cardiovascular events in hemodialysis patients: Do Hyoung Kim, Young-Ki Lee, Juhee Kim et al.; Kidney Res Clin Pract. 2021;40(4):724-733. Published online August 31, 2021; DOI: https://doi.org/10.23876/j.krcp.20.260
Web of Science 1 Cited By 1; Full text PubReader ePub PDF

Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up: Antonio Lacquaniti, Patrizio Pasqualetti, Teresa Casuscelli di Tocco et al.; Kidney Res Clin Pract. 2020;39(3):334-343. Published online September 30, 2020; DOI: https://doi.org/10.23876/j.krcp.20.015
Web of Science 8 Cited By 8; Full text PubReader PDF

The effect of intravenous ascorbic acid in hemodialysis patients with normoferritinemic anemia: Dae Woong Kang, Chi Yong Ahn, Bong Kwan Ryu, Byung Chul Shin, Jong Hoon Chung, Hyun Lee Kim; Kidney Res Clin Pract. 2012;31(1):48-53. Published online January 20, 2012; DOI: https://doi.org/10.1016/j.krcp.2012.01.002
Web of Science 5 Cited By 6; Full text PubReader PDF

Comparison of Once-Biweekly Administration of Epoetin-α with Darbepoetin-α in Chronic Kidney Disease Patients Not Receiving Dialysis: So-Young Kim, M.D., Hae-Jin Choi, M.D., Hye-Jin Choi, M.D., Cho-ee Lee, M.D., Seon-Ung Yun, M.D., Jung-Hwan Park, M.D., Jong-Ho Lee, M.D., Jong-Oh Song, M.D. and Young-Il Jo, M.D.; Korean J Nephrol. 2010;29(5):562-569.; PDF

Erythropoietin (EPO) Attenuates Renal Injury in an Experimental Model of Cisplatin-induced Nephrotoxicity in Rats: Dae Eun Choi, M.D. Sarah Chung, M.D. Young Mo Lee, M.D., Ph.D. Kwang-Sun Suh, M.D., Ph.D. Ki-Ryang Na, M.D., Ph.D. Young-Tai Shin, M.D., Ph.D. and Kang Wook Lee, M.D., Ph.D.; Korean J Nephrol. 2009;28(2):103-112.; PDF

Time-averaged Concentration Hemoglobin and Erythropoietin Requirement According to Hemoglobin of Different Session of HD of the Week: Eun Hee Jang, M.D. Kang Woo Hun, M.D. and Choi So-yeon, M.D.; Korean J Nephrol. 2008;27(3):319-326.; PDF

The Protective Effect of Recombinant Human Erythropoietin and N-acetylcysteine in Radiocontrast-Induced Nephrotoxicity: Sarah Chung, M.D., Eui Sik Kim, M.D., Ji Yoon Jung, M.D. Nan Hee Kim, M.D., Dae Eun Choi, M.D., Ki-Ryang Na, M.D. Kang Wook Lee, M.D. and Young-Tai Shin, M.D.; Korean J Nephrol. 2007;26(6):699-704.; PDF

Original Article : The Efficacy of Once Weekly Compared with Two or Three Times Weekly Subcutaneous Epoetin Alfa (Espogen®): Young Ki Lee, M.D., Hyung Seok Lee, M.D., Min Ha Joo, M.D., Seong Gyun Kim, M.D.Jang Won Seo, M.D., Ji Eun Oh, M.D., Jong Woo Yoon, M.D., Ja Ryong Koo, M.D.Hyung Jik Kim, M.D. and Jung Woo Noh, M.D.; Korean J Nephrol. 2007;26(2):220-226.; PDF

Volume 43, No. 2

Kidney Research
and
Clinical Practice

Print ISSN: 2211-9132
Online ISSN: 2211-9140

Impact Factor

3.0

MOST VIEWED MOST CITED

14,834	Validation of operational definitions of mortality in a nationwide hemodialysis population using the Health Insurance Review and Assessment Service databases of Korea
19,814	C4d Puzzle in ABO-incompatible kidney transplantation
8,268	How should we treat acute kidney injury caused by renal congestion?
12,985	Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
35,022	Uremic pruritus: pathophysiology, clinical presentation, and treatments

Cited By 14	Association between blood pressure and the risk of chronic kidney disease in treatment-naïve hypertensive patients
Cited By 13	Exploring molecular targets in diabetic kidney disease
Cited By 13	Application of C5 inhibitors in glomerular diseases in 2021
Cited By 13	GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
Cited By 11	Prostaglandin E2 receptors as therapeutic targets in renal fibrosis

Editorial Office: #301, (Miseung Bldg.) 23, Apgujenog-ro 30-gil, Gangnam-gu, Seoul 06022, Korea
Tel: +82-2-3486-8736 Fax: +82-2-3486-8737 E-mail: registry@ksn.or.kr

Copyright © 2024 by The Korean Society of Nephrology.